



Neurodegenerative diseases resource bulletin

Overview July 2023



Featured insights


Download our clinical booklet

In this booklet we present and discuss current topics related to early Alzheimer's disease diagnostics:

- Why is early detection important?
- Altered proteins in brain neurodegenerative diseases
- Clinical features and neurodegenerative biomarker changes in cerebrospinal fluid (CSF)
- Handling and transportation of CSF samples
- CSF biochemical pattern interpretation
- A β deposition and clearance: a key feature of the ageing brain
- New criteria for Alzheimer's disease
- Future vision on blood markers

Download the booklet in English or other available translations by [clicking here](#) - or scan the QR code.

Download



Latest News

- Fujirebio further extends its fully automated blood-based biomarker portfolio with the fully automated Lumipulse[®] G ApoE₄ and Lumipulse[®] G Pan-ApoE assays for Research Use Only (March 31, 2023)
- Fujirebio expands its assay menu in the field of neurodegenerative diseases with the launch of the fully automated Lumipulse[®] G NfL CSF and Lumipulse[®] G NfL Blood tests (March 28, 2023)
- AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. announce strategic partnership to advance biomarker development for Alzheimer's disease and neurodegeneration (March 8, 2023)

Go to





Webinar recordings

Current topics in Alzheimer's disease diagnostics

This was our first series of webinars dedicated to current topics in the field of Alzheimer's disease diagnostics and featuring leading expert speakers. You can find all the details about these webinars below along with information about how to watch the webinar recordings in our website.



CSF-based biomarkers to support the diagnosis of Alzheimer's disease

[Watch](#)

- **Daniel Alcolea** - Faculty Neurologist, Sant Pau Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain:

“Positioning of the core CSF biomarkers of Alzheimer's disease: a clinician's perspective”

- **Piotr Lewczuk** - Professor of Neurochemistry and Head, Laboratory for Clinical Neurochemistry and Neurochemical Dementia Diagnostics, Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, Germany:

“Value of the β -Amyloid ratio and other CSF biomarkers in the Erlangen Score interpretation algorithm”



Preparing for the future of blood-based biomarker testing in Alzheimer's disease

[Watch](#)

- **Oskar Hansson** - Professor of Neurology, Lund University and Senior Consultant Neurologist, Memory Clinic, Lund University and Memory Clinic, Skåne University Hospital, Lund, Sweden:

“Is plasma pTau ready for implementation in clinical practice?”

- **Manu Vandijck** - Product Development Manager, Fujirebio Europe, Gent, Belgium:

“Lumipulse G pTau 181 in plasma: where are we today?”



Possible applications for novel CSF biomarkers

[Watch](#)

- **Lucilla Parnetti (moderator)** - Professor of Neurology and Head, Section of Neurology, Department of Medicine and Surgery, University of Perugia, Italy

- **Lorenzo Gaetani** - Clinical Research Fellow, Section of Neurology, Department of Medicine and Surgery, University of Perugia, Italy:

“The potential diagnostic and prognostic value of CSF NFL in different CNS disorders”

- **Charlotte Teunissen** - Professor of Neurochemistry and Head, Neurochemistry Lab, Amsterdam UMC, The Netherlands:

“Capturing the full complexity of Alzheimer's disease with trial outcome measures”



Latest articles

IVDR status update for Fujirebio's Neuro products

The European Union Directive on In Vitro Diagnostic Medical Devices (98/79/EC; IVDD) that sets out the guidance for CE-marking of IVD products was replaced by a new regulation EU/2017/746 as of May 2022 (IVD Regulation).

[Read article](#)

Scientific poster – Analytical performance of the Lumipulse® G NfL CSF <RUO>

This AD/PD 2023 poster wishes to demonstrate the analytical performance of the newly developed Lumipulse G NfL CSF assay.

[Download poster](#)

Scientific poster - Blood sample matrix validation, impact of sample freezing and method comparison analysis using the Lumipulse® G NfL blood prototype assay

This AD/PD 2023 poster investigates the agreement between matched serum and plasma samples on the Lumipulse G NfL Blood assay, the impact of one freeze-thaw cycle of EDTA plasma samples on NfL concentrations, and a method comparison between the Lumipulse assay and a comparative device.



[Download poster](#)

CSF pTau181/Aβ1-42 ratio increases pre-analytical variability over measuring Aβ1-42 alone

In this CTAD 2022 poster, we examine the utility of CSF biomarker ratios to correct for pre-analytical variability.



[Read article](#)

A fully automated and scalable plasma pTau 181 assay for Alzheimer's disease

In this article, the diagnostic performance of a modified version of the Lumipulse G pTau181 CSF test is evaluated.



[Read article](#)

New criteria for Alzheimer's disease

What are the new criteria for different stages of AD, as suggested by the International Working Group (IWG) and the National Institute on Aging-Alzheimer's Association (NIA-AA)?



[Read article](#)

Aβ deposition and clearance: a key feature of the ageing brain

This article looks closer at Aβ deposition and clearance as key feature of the ageing brain.



[Read article](#)

Latest videos

A neurochemist's search to save memories

Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, who was diagnosed with Alzheimer's disease in Charlotte's own laboratory. Hear them talk about the difficult acceptance of the diagnosis and how to live with the disease. And hear about partnering in the search for earlier and better diagnostic testing solutions. [Click here to watch](#), or scan the QR code.



A day at the Fujirebio Neuro Center of Excellence™

The Fujirebio Neuro Center of Excellence is a research and development hub focused on developing diagnostic solutions to neurodegenerative diseases. In this short video we show you around at the Fujirebio Neuro Center of Excellence. Right now, expectations are high for the development of blood tests. Meet the team developing these new tests. [Click here to watch](#), or scan the QR code.



Automated CSF biomarker testing and the benefits of the amyloid ratio

We have developed two short animation videos to help illustrate:

The advantage of automated testing for the four main cerebrospinal fluid (CSF) biomarkers to help with early and reliable Alzheimer's disease diagnosis (click here to watch).



Why and how a ratio calculation of the two amyloid proteins, A β 1-42 and A β 1-40, offers particularly essential information about the buildup of amyloid pathology in a patient's brain (click here to watch).



Daniel's story about living with Alzheimer's disease

Daniel lives in Stockholm, Sweden, and was diagnosed with Alzheimer's disease when he was still in his early 50's. In this 6-minute video we follow Daniel and his wife Sophia. We listen to their story from the first symptoms and suspicion, through biomarker testing and diagnosis and to today, where Daniel and Sophia and their family live with the disease. And we hear about their hopes for the future. [Click here to watch](#), or scan the QR code.



Upcoming events



JUL 16, 2023 - JUL 20, 2023
AMSTERDAM, NETHERLANDS

AAIC 2023 - Alzheimer's Association International Conference®



SEP 18, 2023 - SEP 20, 2023
BORDEAUX, FRANCE

RFMASA 2023 - les Rencontres Francophones sur la Maladie d'Alzheimer et les Syndromes Apparentés



SEP 19, 2023 - SEP 22, 2023
MÁLAGA, SPAIN

NEURO 2023 - International Congress on Neurodegenerative Diseases



OCT 12, 2023 - OCT 13, 2023
INNSBRUCK, AUSTRIA

ÖAG - 35. Jahrestagung der Österreichischen Alzheimer Gesellschaft



OCT 24, 2023 - OCT 27, 2023
BOSTON (MA), USA

CTAD 2023 - 16th Clinical Trials on Alzheimer's Disease Congress



MAR 5, 2024 - MAR 9, 2024
LISBON, PORTUGAL

AD/PD 2024 - International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders

[More info](#)





Full resource overview

Articles

- IVDR status update for Fujirebio's Neuro products
- CSF pTau181/Aβ1-42 ratio increases pre-analytical variability over measuring Aβ1-42 alone
- A fully automated and scalable plasma pTau181 assay for Alzheimer's disease
- New criteria for Alzheimer's disease
- Aβ deposition and clearance: a key feature of the ageing brain
- CSF biochemical pattern interpretation
- Using CSF biomarkers to link pathology and clinical presentation
- Altered proteins in brain neurodegenerative diseases

[View all](#)

Webinars

- CSF-based biomarkers to support the diagnosis of Alzheimer's disease
- Preparing for the future of blood-based biomarker testing in Alzheimer's disease
- Possible applications for novel CSF biomarkers

[Watch](#)

Videos

- A neurochemist's search to save memories [06:15]
- A day at the Fujirebio Neuro Center of Excellence [02:04]
- The interest of automated testing for all four CSF biomarkers [01:41]
- Ratio calculation of Aβ1-42 and Aβ1-40 offers essential information about the buildup of amyloid pathology in a patient's brain [02:00]
- Daniel's story of living with Alzheimer's disease and his hopes for the future [06:34]

[Watch](#)

Leaflets and booklets

- Our clinician booklet "A few drops of insight can lead to an ocean of understanding" (PDF or print)
- Our leaflet introducing the Fujirebio Neuro Center of Excellence (PDF or print)
- Our product leaflet presenting the fully automated Lumipulse G Neuro panel (PDF or print)

[Contact us](#)

Related products

- Details on our full range of products related to Alzheimer's can be found on our website

[Go to](#)

**Fujirebio
Neuro Center
of Excellence**

A world-leading hub for expertise in neurodegenerative disease diagnostics

The Fujirebio Neuro Centre of Excellence™ has been founded to help tackle the challenges of neurodegenerative diseases like Alzheimer's and Parkinson's. It is a knowledge-sharing meeting point between our expert teams and neuro professionals, and serves as a catalyst for collaborations and partnerships with laboratories, CDMOs, pharma companies, clinicians, researchers, and academia worldwide. It is also a ray of hope for patients, families, and caregivers.

Contact us:

Fujirebio Neuro Center of Excellence

Technologiepark 6

9052 Gent, Belgium

+32 9 329 13 29

+32 9 329 19 11

FNCE@fujirebio.com

